ArticlePLoS neglected tropical diseases2022
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.
Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Amino acid substitutions at the G118 hotspot in dihydroorotate dehydrogenase confer olorofim resistance inMicrobiology spectrum · 2026Article
- Mycetoma.PLoS neglected tropical diseases · 2026Review
- Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.Microbiology spectrum · 2026Article
- Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.Journal of fungi (Basel, Switzerland) · 2026Review
- A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma.The Journal of antimicrobial chemotherapy · 2025Article
- Eumycetoma: pathogenesis, current treatments, and the search for new drugs.Applied microbiology and biotechnology · 2025Review
- Antiparasitic and Antifungal Activities of Cetyl-Maritima, a NewAntibiotics (Basel, Switzerland) · 2025Article
- Special Issue "Antifungal Drug Discovery: Progresses, Challenges, Opportunities".International journal of molecular sciences · 2025Article
- Review
- Screening of the Pandemic Response Box library identified promising compound candidate drug combinations against extensively drug-resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives.Biomedicines · 2024Article
- Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity againstInternational journal of molecular sciences · 2024Article
- Identifying Fast and Slow-Acting Antimalarial Compounds of Pandemic Response Box Against Blood-Stage Culture of Plasmodium falciparum 3D7.Current microbiology · 2024Article
- Screening of the Pandemic Response Box identifies anti-microsporidia compounds.PLoS neglected tropical diseases · 2023Article
- Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage ofTropical medicine and infectious disease · 2023Article
- The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.Medical mycology · 2023Article
- Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2023Article
- Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.PLoS neglected tropical diseases · 2023Article
- The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration.Parasites & vectors · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eumycetoma is a chronic subcutaneous neglected tropical disease that can be caused by more than 40 different fungal causative agents. The most common causative agents produce black grains and belong to the fungal orders Sordariales and Pleosporales. The current antifungal agents used to treat eumycetoma are itraconazole or terbinafine, however, their cure rates are low. To find novel drugs for eumycetoma, we screened 400 diverse drug-like molecules from the Pandemic Response Box against common eumycetoma causative agents as part of the Open Source Mycetoma initiative (MycetOS). 26 compounds were able to inhibit the growth of Madurella mycetomatis, Madurella pseudomycetomatis and Madurella tropicana, 26 compounds inhibited Falciformispora senegalensis and seven inhibited growth of Medicopsis romeroi in vitro. Four compounds were able to inhibit the growth of all five species of fungi tested. They are the benzimidazole carbamates fenbendazole and carbendazim, the 8-aminoquinolone derivative tafenoquine and MMV1578570. Minimal inhibitory concentrations were then determined for the compounds active against M. mycetomatis. Compounds showing potent activity in vitro were further tested in vivo. Fenbendazole, MMV1782387, ravuconazole and olorofim were able to significantly prolong Galleria mellonella larvae survival and are promising candidates to explore in mycetoma treatment and to also serve as scaffolds for medicinal chemistry optimisation in the search for novel antifungals to treat eumycetoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.